Takeda Pharmaceutical (TAK) Net Cash Flow (2018 - 2026)

Takeda Pharmaceutical's Net Cash Flow history runs 9 years deep, the most recent figure standing at -$388.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 40.27% year-over-year to -$388.8 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 378.88% YoY), while the FY2026 annual figure was $1.2 billion, up 389.65% from the prior year.
• Net Cash Flow was -$388.8 million for Q1 2026 at Takeda Pharmaceutical, down from -$318.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.4 billion in Q1 2024 to a low of -$2.6 billion in Q4 2024.
• Historically, Net Cash Flow has averaged $62.0 million across 5 years, with a median of -$179.8 million in 2023.
• Biggest YoY gain for Net Cash Flow was 4081.95% in 2024; the steepest drop was 1318.55% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$732.0 million in 2022, then soared by 75.44% to -$179.8 million in 2023, then sank by 1318.55% to -$2.6 billion in 2024, then jumped by 87.52% to -$318.4 million in 2025, then dropped by 22.14% to -$388.8 million in 2026.
• The last three Net Cash Flow figures came in at -$388.8 million (Q1 2026), -$318.4 million (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.